Nifty Pharma Index dips 1.8% on Trump Tariff concerns: Aurobindo, Cipla, Lupin among key losers
Ujjval Jauhari
Published 6 May 2025, 09:31 AM IST Stock Market Today: Nifty Pharma Index saw shar correction
Stock Market Today: Nifty Pharma Index saw steep cuts of more than 1.8% in the morning trades on Tuesday amidst Trump Tariff concerns: Aurobindo, Cipla, Lupin share prices were among key losers
First Published: 6 May 2025, 09:31 AM IST
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
15 hours ago
- Time of India
Cipla Share Price Live Updates: Cipla's Volume Overview
10 Jun 2025 | 08:43:16 AM IST Welcome to the Cipla Stock Liveblog, your real-time source for the latest updates and comprehensive analysis on a prominent stock. Dive into the current details of Cipla, including: Last traded price 1506.6, Market capitalization: 120317.59, Volume: 689631, Price-to-earnings ratio 22.82, Earnings per share 65.28. Our liveblog offers a complete overview of Cipla through a blend of fundamental and technical indicators. Stay informed about breaking news that can shape Cipla's performance in the market. Our market analysis and expert opinions empower you to make informed investment decisions. Join us as we unravel the potential of Cipla in the ever-changing market landscape. The data points are updated as on 08:43:16 AM IST, 10 Jun 2025 Show more
Mint
2 days ago
- Mint
Afcons Infrastructure share price rises 6% on a large order win from Reliance
Ujjval Jauhari Published 9 Jun 2025, 09:33 AM IST Stock Market Today: Afcons Infrastructure's large order win from Reliance. Stock Market Today: Afcons Infrastructure share price rises 6% during the intraday trades on a large order win from Reliance. The Letter of Award (LoA) from Reliance Industries Limited is worth ₹ 700 crore
Business Standard
2 days ago
- Business Standard
Lupin gets USFDA nod for Oxcarbazepine ER tablets
Lupin announced that it has received tentative approval from the U.S Food and Drug Administration (US FDA) for its abbreviated new drug application for Oxcarbazepine extended-release (ER) tablets. Oxcarbazepine ER tablets, 150 mg, 300 mg, and 600 mg are bioequivalent to Oxtellar XR ER tablets, 150 mg, 300 mg, and 600 mg, of Supernus Pharmaceuticals, Inc., and are indicated for the treatment of partial-onset seizures in patients 6 years of age and older. This product would be manufactured at Lupins Nagpur facility in India. Oxcarbazepine ER tablets (RLD Oxtellar XR) had estimated annual sales of $206 million in the U.S. (IQVIA MAT April 2025). Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The companys consolidated net profit surged 114.9% to Rs 772.52 crore on 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24. The scrip rose 0.20% to end at Rs 1,999.20 on the BSE.
